What's in Medicure's pipeline?

Medicure has 4 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Medicure's portfolio?

No competitive overlap detected.

Subscribe to /feed/company/medicure.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Medicure pipeline: 1 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Drug	Generic	Phase	Class	Target	Area	First approval
Aggrastat	TIROFIBAN	marketed	Platelet Aggregation Inhibitor	Integrin alpha-IIb/beta-3	Cardiovascular	1998-01-01
(MC-1) Pyridoxal 5'-phosphate	(MC-1) Pyridoxal 5'-phosphate	phase 3	Vitamin B6 supplement / Cofactor replacement	Pyridoxal kinase substrate; cofactor for aminotransferases and decarboxylases	Cardiovascular / Metabolic / Neurology

No regulatory actions in the last 90 days for this portfolio.

No PDUFA dates in the next 180 days for this portfolio.

No upcoming patent expiries for this portfolio.

No competitive overlap data.

Every new pipeline event for Medicure:

Drug Landscape (2026). Medicure — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medicure. Accessed 2026-05-13.